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Abst rac t
Background and purpose: Matrix metalloproteinase 9
(MMP-9) is an endopeptidase degrading extracellular matrix.
There is growing evidence that changes in extracellular matrix
play an important role in vascular pathology, especially in 
cardiovascular and cerebrovascular disease. Previous studies
have demonstrated that MMP-9 activity is controlled by
–1562 C/T polymorphism. Genotypes with T allele (CT, TT)
have higher enzymatic activity. Thus, this polymorphism
could be responsible for the higher risk for cerebrovascular
disease and death. The aim of this study was to assess the sig-
nificance of MMP-9 polymorphism as a risk factor for cere-
brovascular disease in a Polish population.
Material and methods: A total of 775 consecutive patients
with a diagnosis of cerebrovascular disease (ischaemic stroke,
intracerebral haemorrhage, subarachnoid haemorrhage)
admitted to the Stroke Unit, Jagiellonian University, Krakow,
Poland between 2000 and 2004 were studied and compared
with 766 matched controls. The polymorphism was studied
by polymerase chain reaction (PCR) and restricted enzyme
digestion.
Results: Among 418 patients with ischaemic stroke of 
various aetiologies and among 146 patients with primary
intracerebral haemorrhage and 211 patients with subarach-
noid haemorrhage due to ruptured intracranial aneurysm,
statistical analysis did not show a significant difference
between occurrence of CC, CT, TT genotypes or C and T
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St reszczenie
Wstêp i cel pracy: Metaloproteinaza 9 (MMP-9) jest endo-
peptydaz¹ degraduj¹c¹ macierz zewn¹trzkomórkow¹. Istnie-
je coraz wiêcej dowodów naukowych potwierdzaj¹cych wa¿n¹
rolê zmian w macierzy zewn¹trzkomórkowej w chorobach
naczyniowych, a szczególnie w chorobach serca i naczyñ
mózgowych. Badania dowiod³y, ¿e aktywnoœæ MMP-9 jest
zale¿na od polimorfizmu –1562 C/T. Genotypy z allelem T
(CT, TT) wykazuj¹ wiêksz¹ aktywnoœæ enzymatyczn¹, co
mo¿e przyczyniaæ siê do znaczenia tego polimorfizmu jako
czynnika ryzyka chorób naczyniowych mózgu i œmierci.
Celem tego badania by³a analiza zwi¹zku wariantów poli-
morficznych genu MMP-9 z chorobami naczyniowymi
mózgu w badanej populacji polskiej.
Materia³ i metody: Badano ³¹cznie 775 pacjentów przyjêtych
na Oddzia³ Udarowy Kliniki Neurologii Uniwersytetu Jagiel-
loñskiego w latach 2000–2004 z rozpoznaniem choroby
naczyñ mózgowych (tj. udaru niedokrwiennego, krwotoku
œródmózgowego lub krwotoku podpajêczynówkowego) oraz
766 osób z grupy kontrolnej. Polimorfizm genu MMP-9 bada-
no za pomoc¹ techniki PCR i trawienia przy u¿yciu enzymu
restrykcyjnego.
Wyniki: Analiza statystyczna nie wykaza³a istotnych ró¿nic
w wystêpowaniu genotypów CC, CT i TT ani alleli C i T
u 418 chorych na udar niedokrwienny o ró¿nej etiologii, 
146 osób z pierwotnym krwotokiem œródmózgowym ani
u 211 chorych z krwotokiem podpajêczynówkowym z pêk-
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alleles in patients with stroke of various aetiology compared
with controls. 
Conclusions: We found no association between the –1562 C/T
MMP-9 polymorphism and ischaemic stroke, subarachnoid
haemorrhage or spontaneous intracerebral haemorrhage in
the studied Polish population.
Key words: –1562 C/T polymorphism of MMP-9 gene,
matrix metalloproteinase-9, cerebrovascular disease.
niêtego têtniaka wewn¹trzczaszkowego w porównaniu z oso-
bami z grupy kontrolnej. 
Wnioski: Nie odnaleziono zwi¹zku polimorfizmu –1562 C/T
genu MMP-9 z wystêpowaniem udaru niedokrwiennego
o ró¿nej etiologii, krwotoku podpajêczynówkowego i pierwot-
nego krwotoku œródmózgowego w badanej populacji polskiej. 
S³owa kluczowe: polimorfizm –1562 C/T genu MMP-9,
metaloproteinaza 9, choroba naczyñ mózgowych.
Introduction
Matrix metalloproteinase 9 (gelatinase B, MMP-9)
is an endopeptidase degrading extracellular proteins,
mostly gelatine and collagen type IV (native protein).
MMP-9 can be expressed by many cells, especially by
endothelial cells, monocytes and macrophages. This
enzyme plays an important role in both physiological
(embryogenesis, angiogenesis) and pathological (car-
cinogenesis, arthritis, pulmonary diseases) processes [1].
Previous studies have demonstrated that MMP-9 activ-
ity is controlled by several MMP-9 gene polymorphisms
[2]. The MMP-9 gene is located on chromosome
20q11.2-q13 and several polymorphisms in the pro-
moter, coding, and untranslated regions (UTR) have
been reported [3-5], with the –1562 C/T polymorphism
most extensively studied [6]. This polymorphism in the
promoter region of the MMP-9 gene is probably func-
tional in transcriptional regulation [2]. A recent study
revealed that the CC genotype is responsible for lower
activity of MMP-9 and genotypes with the T allele 
(CT, TT) are responsible for higher activity [7]. The
aim of our study was to assess the significance of the 
–1562 C/T polymorphism of the MMP-9 gene as a risk
factor for different types of cerebrovascular diseases, i.e.
ischaemic stroke, ICH and SAH from ruptured
aneurysm.
There is growing evidence that extracellular matrix
plays an important role in cardiovascular and cere-
brovascular diseases [8]. Higher expression of 92-kDa
gelatinase (MMP-9) using in situ zymography was
found in atherosclerotic plaques obtained during
endarterectomy or autopsy [9]. Increased expression of
MMP-9 using in situ zymography was also found in
the wall of cerebral aneurysms [10]. The concentration
of MMP-9 in plasma correlates with neurological deficit
and infarct volume of stroke patients [11], as well as
with the risk of haemorrhagic transformation of car-
dioembolic stroke [12,13]. Increased concentration of
MMP-9 was also found in plasma of patients with
intracerebral haemorrhage (ICH) [14]. 
The effect of the –1562 C/T MMP-9 polymorphism
on the risk of cerebrovascular diseases was studied only
in patients with subarachnoid haemorrhage (SAH) from
ruptured aneurysm, showing negative results [15,16].
Material and methods
The study population consisted of 1016 unrelated
patients with a diagnosis of cerebrovascular disease
prospectively recruited at the Stroke Unit, Neurology
Department, University Hospital, Krakow, Poland
between 2000 and 2004. The Unit serves as a stroke
emergency centre for one district of Krakow and as
a referral centre for a region of 1.5 million citizens. We
excluded patients with coexisting cancer or not agree-
ing to participate in the study. Among 643 ischaemic
stroke patients selected from 714 patients, 225 had
a stroke of unknown aetiology and were excluded, leav-
ing 418 patients eligible for the study. We also included
211 patients with SAH (out of 281 patients). We also
involved 146 patients with ICH (out of 182 patients).
We studied 766 unrelated control individuals, free of
clinically detectable cerebrovascular disease and with-
out any stroke history, as well. They were recruited from
consecutive spouses of the patients (30%) or from the
community. Controls were randomly matched from the
beginning of the study for age (± 2 years) and gender
with patients for each studied group separately.
Ischaemic stroke aetiologies were diagnosed using
TOAST criteria [17]. Only patients with established
stroke aetiology were included in the study. The diag-
nosis of SAH was confirmed by computed tomography
(CT), and/or lumbar puncture, and the diagnosis of
ruptured saccular aneurysm was established by digital
subtraction angiography (DSA) or angio-CT. ICH was
diagnosed by CT. Vascular malformations were exclud-
ed by means of DSA or magnetic resonance (MR). 
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Demographic data and vascular risk factors profile
were collected for all patients and their controls in each
study group. An individual was classified as having arte-
rial hypertension if he/she met at least one of the fol-
lowing criteria: 1) the diagnosis of hypertension in the
past medical history; 2) antihypertensive treatment 
prior to entry into the study; 3) systolic or diastolic blood
pressure ≥ 140 mm Hg or ≥ 90 mm Hg, respectively,
on at least two different occasions (the first three days
of hospitalization were not considered for the stroke
patients). The history of ischaemic heart disease was
based on medical history, examination of previous and
current ECGs, and laboratory data. The diagnosis of
atrial fibrillation was based on ECG findings during
hospitalization, or on data from medical documentation
with ECG-documented atrial fibrillation. Diabetes mel-
litus was defined by WHO criteria [18]. Family histo-
ry of stroke was defined as the occurrence of stroke in
first degree relatives. Smoking habits were defined as
current smokers of ≥ 1 cigarette per day, former smok-
ers, or non-smokers. For statistical analysis, ‘current’
and ‘former’ smokers were pooled together. 
The study was approved by the University Ethical
Committee and was performed in accordance with the
Helsinki Declaration.
Ten mL blood samples were collected from all
patients and controls for probes with EDTA. Labora-
tory personnel, blinded to sample identity, performed
the genetic analyses. The genotyping for MMP-9 poly-
morphism was established by polymerase chain reactions
(PCR) and restriction enzyme digestions using the
method previously reported [3]. 
Data on quantitative characteristics are expressed as
means ± standard deviations (SD). Data on qualitative
characteristics are expressed as percent values or absolute
numbers, as indicated. Comparisons between groups
were made with χ2 test (nominal data) or Student’s 
t-test (interval data). A p-value < 0.05 was considered
statistically significant. 
Hardy-Weinberg equilibrium was tested by the χ2
method. The sample sizes were calculated with a pow-
er of 80% to detect the difference between the frequen-
cies of alleles at the 0.05 significance level. The asso-
ciation of the –1562 C/T MMP-9 polymorphism with
the risk of cerebrovascular disease was investigated by
means of logistic regression analysis. For multivariate
risk predictors, adjusted odds ratios (ORs) are given
with the 95% confidence intervals (CIs).
The calculations were performed using the data
analysis software program SPSS 10 for Windows (SPSS
Inc. 2000).
Results
We studied 96 stroke patients with large vessel disease
(LVD) (23% of all stroke patients), 100 stroke patients
with small vessel disease (SVD) (24% of all stroke
patients), and 222 patients with cardioembolic stroke (CE)
(53% of all stroke patients). The control group consisted
of 408 subjects. Patients with LVD and SVD stroke had
hypertension, hypercholesterolaemia and diabetes more
often than controls. Patients with CE stroke additionally
more often had ischaemic heart disease and atrial fibrilla-
tion as compared to controls (Table 1). The CC, CT and
TT genotypes of the MMP-9 gene, determined in 
826 individuals, were in Hardy-Weinberg equilibrium for
the total group and for patients with different stroke aeti-
ologies and controls separately (p > 0.1 for each group). 
The distribution of genotypes and alleles in patients
with different ischaemic stroke aetiologies was similar to
that in the controls (Table 1). Independent risk factors for
SVD stroke were hypercholesterolaemia and hypertension,
for LVD stroke were smoking, hypercholesterolaemia, and
hypertension. Independent risk factors for CE stroke were
hypercholesterolaemia, hypertension, ischaemic heart 
disease, and atrial fibrillation. Logistic regression analysis
showed that genotypes with the T allele were not an in-
dependent risk factor for stroke of different aetiologies
(Table 2).
One hundred and forty-six patients with ICH dif-
fered from their controls in respect of hypertension and
hypercholesterolaemia. The distribution of the geno-
types and alleles of the studied polymorphism was simi-
lar to that in the controls (Table 3). An independent risk
factor was hypertension. Logistic regression analysis
showed that genotypes with the T allele were not an
independent risk factor for ICH (Table 4).
Patients with SAH more often had hypertension, dia-
betes and hypercholesterolaemia and were more often
smokers (current and previous ones) (Table 3). Genotype
and allele frequencies did not differ significantly between
SAH patients and controls (Table 3). Independent risk
factors were hypertension and smoking. Hypercholes-
terolaemia and ischaemic heart disease were independent
factors decreasing the risk of SAH. Logistic regression
analysis showed that genotypes with the T allele were not
an independent risk factor for SAH (Table 4).
Discussion
This study did not show any significant relationship
between the –1562 C/T polymorphism of the MMP-9
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Risk factor SVD stroke LVD stroke CE stroke Controls P-value P-value P-value
(n = 100) (n = 96) (n = 222) (n = 408) for for for
(24% of all (23% of all  (53% of all  SVD stroke vs. LVD stroke vs. CE stroke vs.
ischaemic stroke) ischaemic stroke) ischaemic stroke) controls controls controls
Age, years (mean ± SD) 62.8 ± 11.9 66.3 ± 11.6 70.2 ± 13.4 64.4 ± 18.4 NS NS NS
Sex, male/female ratio 57/43 61/35 87/135 195/213 NS NS NS
Hypertension, n (%) 77 (77.0) 79 (82.3) 189 (85.1) 177 (43.4) 0.0011 0.0003 < 0.00001
Ischaemic heart disease, n (%) 29 (29.0) 40 (41.7) 170 (76.6) 105 (25.7) NS 0.026 < 0.00001
Atrial fibrillation†, n (%) 0 (0) 0 (0) 159 (71.6) 32 (7.8) 0.0054 0.0064 < 0.00001
Hypercholesterolaemia, n (%) 62 (62.0) 61 (63.5) 101 (45.5) 66 (16.2) < 0.00001 < 0.00001 < 0.00001
Diabetes mellitus, n (%) 19 (19.0) 19 (19.8) 34 (18.2) 1 (0.2) < 0.00001 < 0.00001 < 0.00001
Smoking (current/previous), n (%) 41 (41.0) 41 (42.7) 51 (27.3) 148 (36.3) NS NS 0.0119
Genotype
CC, n (%) 79 (79.0) 67 (69.8) 169 (76.1) 291 (71.3) NS* NS* NS*
CT, n (%) 19 (19.0) 25 (26.0) 45 (20.3) 111 (27.2) NS** NS** NS**
TT, n (%) 2 (2.0) 4 (4.2) 8 (3.6) 6 (1.5)
Allele
C, n (%) 177 (88.5) 159 (82.8) 383 (86.3) 693 (84.9) NS*** NS*** NS***
T, n (%) 23 (11.5) 33 (17.2) 61 (13.7) 123 (15.1)
Table 1. Demographics, risk factor profiles, and MMP-9 genotypes and allele distribution in patients with different ischaemic stroke aetiologies and their matched controls
SVD stroke indicates small vessel disease stroke, LVD stroke indicates large vessel disease stroke, CE stroke indicates cardioembolic stroke; SD indicates standard deviation
†atrial fibrillation was not considered as a risk factor for LVD stroke and SVD stroke
* statistical calculation based on the comparison of CC vs. CT and TT genotypes (χ2 test)
** statistical calculation based on the comparison of CC and CT vs. TT genotypes (χ2 test)
*** statistical calculation based on the comparison of C vs. T alleles (χ2 test)
–1562 C/T MMP-9
polymorphism and cerebrovascular disease
Neurologia i Neurochirurgia Polska 2010; 44, 4354
gene and ischaemic stroke (regardless of aetiology), ICH
and SAH from ruptured aneurysm.
So far, MMP-9 has been extensively studied in plaque
formations in coronary and carotid arteries.
Matrix metalloproteinases influence the process of
plaque formation by facilitating migration of vascular
smooth cells into the intimal space. They also degrade the
fibrous cap, causing rupture of the plaque [19]. A study
performed by Loftus et al. showed an increased level of
MMP-9 in unstable carotid plaques as compared to 
stable carotid plaques [20] and a correlation between 
the MMP-9 levels in plasma with carotid plaque insta-
bility [21]. Studies in patients with ischaemic heart dis-
ease proved more severe coronary atherosclerosis evaluat-
ed by angiography in patients carrying one or two copies
of the T allele [3]. Coronary artery disease and large 
vessel disease stroke present with common pathophysio-
logical features; both are the result of plaque formation.
Therefore, we speculated that the MMP-9 C/T polymor-
phism might also affect the risk of stroke due to LVD.
There are a few explanations for the lack of association
between the C/T polymorphism and the risk of LVD in
the present study. It may be due to the fact that many
T allele carriers died before the development of LVD
stroke. As a result, the prevalence of ischaemic heart dis-
ease in the cases was similar to that in the controls. It can-
not be excluded that the lack of significance of the studied
polymorphism in LVD stroke is a consequence of the 
activity of unknown factors modifying the function of
MMP-9 more strongly than the polymorphism. The lack
of association between the studied polymorphism and
ischaemic stroke, both due to LVD and other aetiologies,
in our study may support the hypo thesis of Montaner 
et al. [22] that this polymorphism is not functional in cere-
bral ischaemia in vivo. However, this study was based on
a small number of patients with stroke mostly of cardio-
embolic aetiology. Those authors also found that high plas-
ma levels of MMP-9 did not correlate with presence of
the T allele but with the theo retically low-function alleles
(CC) in their studied group. 
Engagement of MMP-9 in the pathogenesis of ICH
was documented in animal studies on ICH due to cere-
bral amyloid angiopathy. These experiments showed
increased production of MMP-9 in cerebral endothelial
cells in mice stimulated by amyloid-beta peptide or in
transgenic mice with overexpression of Swedish mutation
of amyloid precursor protein (APPsw) [23]. Other ani-
mal data showed a correlation between MMP-9 in rat
brain using zymography and damage of the blood-brain
barrier [24]. They also showed that brain oedema follow-
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Risk factors ICH Controls P-value SAH Controls P-value
(n =146) (n =146) for (n = 211) (n = 212) for
ICH SAH 
vs. controls vs. controls
Age, years  (mean ± SD) 63.9 ± 13.6 63.9 ± 13.7 NS 50.5 ± 12.3 50.5 ± 12.3 NS
Sex, male/female ratio 81/65 81/65 NS 95/116 96/116 NS
Hypertension, n (%) 117 (80.1) 67 (45.9) 0.0037 123 (58.3) 75 (35.4) 0.0044
Ischaemic heart disease, n (%) 51 (34.9) 50 (34.2) NS 36 (17.1) 35 (16.5) NS
Hypercholesterolaemia, n (%) 7 (4.8) 25 (17.1) 0.0025 32 (15.2) 14 (6.6) 0.0112
Diabetes, n (%) 25 (17.1) 13 (8.9) NS 11 (5.2) 1 (0.5) 0.0043
Smoking, n (%) 62 (42.5) 52 (35.6) NS 111 (52.6) 76 (35.8) 0.0307
Genotype
CC, n (%) 109 (74.7) 104 (71.2) NS* 145 (68.7) 152 (71.7) NS*
CT, n (%) 34 (23.2) 39 (26.7) NS** 60 (28.4) 57 (26.9) NS**
TT, n (%) 3 (2.1) 3 (2.1) 6 (2.9) 3 (1.4)
Allele
C, n (%) 252 (86.3) 247 (84.6) NS*** 350 (82.9) 361 (85.1) NS***
T, n (%) 40 (13.7) 45 (15.4) 72 (17.1) 62 (14.9)
Table 3. Demographics, risk factor profiles, and MMP-9 genotypes and allele distribution in patients with ICH, SAH and their matched controls
ICH indicates intracerebral haemorrhage, SAH indicates subarachnoid haemorrhage, SD indicates standard deviation
* statistical calculation based on the comparison of CC vs. CT and TT genotypes (χ2 test)
** statistical calculation based on the comparison of CC and CT vs. TT genotypes (χ2 test)
*** statistical calculation based on the comparison of allele C vs. T (χ2 test)
ing ICH can be weakened by a specific MMP-9
inhibitor [25,26]. Studies in humans showed that the
level of MMP-9 in plasma correlated with the volume
of oedema due to ICH haemorrhage [27] and with
worsening of the neurological deficit [14]. Since the
studied polymorphism affects enzymatic activity we pos-
tulated that it can be a risk factor for developing ICH.
The negative results of our study can be explained by
the different role of MMP-9, more a marker of the
severity of brain oedema than a risk factor of ICH.
Another explanation may be that they are due to selec-
tion bias, which will be mentioned below.
To date the –1562 C/T polymorphism of the MMP-9
gene has been examined in two studies in patients with
SAH due to ruptured aneurysm [15,16]. Despite the neg-
a tive results of the previous and the current studies, we 
cannot exclude the possible role of MMP-9 in aneurys-
mal SAH. MMP-9 has proteolytic activity against ela-
stin and collagen IV, a major component of the basement
membrane that surrounds vascular smooth muscle cells
and underlies the endothelium in the blood vessel wall
[3]. It has been demonstrated that the development and
rupture of aneurysms is associated with collagen and
elastin degradation. Elastin proteolysis is mostly relat-
ed to vessel wall dilatation, while collagen degradation
is more important in aneurysmal rupture [7]. Interest-
ingly, increased expression of MMP-9 was observed in
abdominal aortic aneurysm.
The lack of a correlation between the –1562 C/T
MMP-9 polymorphism and the risk of cerebrovascular
disease in our study could be explained by the fact 
that elevation of MMP-9 in stroke, ICH and aneurys-
mal SAH may not be determined by a genetic variant of
the MMP-9 gene, but could be a result of its uncon-
trolled release due to other non-specific factors [28,29].
It cannot be excluded that other non-genetic mecha-
nisms may influence the overexpression of MMP-9.
These mechanisms consist of (1) regulation of tran-
scription by interleukin-1 (IL-1), platelet-derived
growth factor (PDGF), tumour necrosis factor-α
(TNF-α), and epidermal growth factor (EGF) through
several cis elements including 2 AP-1 sites, the PEA3
motif, and the consensus sequence for binding of nuclear
factor-kB; (2) inhibition of MMP-9 activity by tissue
–1562 C/T MMP-9 polymorphism and cerebrovascular disease
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inhibitors of metalloproteinases (TIMPs); and (3) regu-
lation of active MMP-9 level by TIMPs or other inhi-
bitors such as alpha 2-macroglobulin or alpha 1-anti-
trypsin [22]. Thus, different mechanisms such as
regulation of transcription, activation of latent MMPs
and inhibition of MMP-9 activity by TIMPs can influ-
ence the impact of an MMP on extracellular matrix
degradation [22].
Ischaemic stroke, ICH and aneurysmal SAH are
common multifactorial diseases. The genetic factor, i.e.
–1562 C/T MMP-9 polymorphism, may be insignifi-
cant when present alone. However, its co-occurrence
with other common clinical risk factors in the same sub-
ject can give rise to a highly significant risk of a disease.
Certain classical clinical risk factors indicate a much
higher risk for those patients who are carriers of certain
genetic mutations [30]. We cannot exclude that inter-
actions between –1562 C/T MMP-9 genotypes and cer-
tain clinical risk factors can increase the relative risk for
some types of cerebrovascular disease.
A potential limitation of our study, as in all studies
on genetic risk factors, is a selection bias related to loss
of the most severely affected patients. In our current
study 10% of ischaemic stroke patients, 20% of ICH
patients, and 25% of SAH patients did not fulfil the
inclusion criteria. We are also aware that some patients
die before admission to the hospital, i.e. 15% of SAH
patients [31]. It is possible that the most severely affect-
ed patients have a different genetic profile and it could
influence the final result. 
We did not take into consideration the plausible
influence of medication, e.g. aspirin, on the phenotypic
effect of –1562 C/T MMP-9 polymorphism. It would
be interesting to study the genotype-phenotype correla-
tions of the MMP-9 gene in aspirin users/non-users and
other ischaemic stroke patient subpopulations.
Conclusion
The –1562 C/T polymorphism of the MMP-9 gene
is not associated with the risk of ischaemic stroke,
aneurysmal SAH, or ICH.
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